Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality and
has an increasing incidence worldwide. Locoregional therapies, defined as imaging-guided …

The prevalence of hepatocellular carcinoma (HCC) is increasing worldwide, whereas that of
most other cancers is decreasing. Non-alcoholic fatty liver disease (NAFLD), which has …

The neutrophil-to-lymphocyte ratio (NLR) is an inflammatory marker which has been
investigated as a prognostic indicator in post-therapeutic recurrence and survival of patients …

The aim of any oncological treatment is not just to eliminate the tumour, but to maximise
patient survival and quality of life. Since the liver has a vital function, any radical treatment …

Incomplete radiofrequency ablation (IRFA) triggers mild protective autophagy in residual
tumor cells and results in an immunosuppressive microenvironment. This accelerates the …

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality
worldwide. The Brazilian Society of Hepatology (SBH) published in 2015 its first …

Simple Summary Decompensated patients with hepatocellular carcinoma (HCC) are a wide
patient category with limited therapeutic options, and are often excluded from existing trials …

Hintergrund Das hepatozelluläre Karzinom (HCC) ist das fünfthäufigste Tumorleiden
weltweit. Da viele HCCs bereits zum Zeitpunkt der Erstdiagnose nicht resektabel sind …

Abstract In the United States, 80%-90% of primary hepatic tumors are hepatocellular
carcinomas and 10%-15% are cholangiocarcinomas (CCA), both with high mortality rate …

Introduction Surgical resection and radiofrequency ablation are preferred options for early-
stage disease. With the increasing availability of therapeutic options understanding the …